Source:http://linkedlifedata.com/resource/pubmed/id/12445886
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:dateCreated |
2002-11-26
|
| pubmed:abstractText |
Tissue factor pathway inhibitor (TFPI), as a primary inhibitor of TF-induced coagulation, reduces neointimal formation and luminal stenosis by inhibiting coagulation and thrombosis after vessel wall injury. Here, we investigated the effect of TFPI gene delivery with a HVJ-AVE liposome vector on restenosis in atherosclerotic arteries after angioplasty in rabbits. We also evaluated the safety of the novel gene therapeutic strategy to prevent restenosis.
|
| pubmed:language |
eng
|
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:author |
pubmed-author:EnjyojiKeiichiK,
pubmed-author:IkedaYoshihikoY,
pubmed-author:Ishibashi-UedaHatsueH,
pubmed-author:KanedaYasufumiY,
pubmed-author:KatoHisaoH,
pubmed-author:NonogiHiroshiH,
pubmed-author:TsukamotoYoshitaneY,
pubmed-author:YasudaSatoshiS,
pubmed-author:YinXinhuaX,
pubmed-author:YutaniChikaoC
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
454-63
|
| pubmed:dateRevised |
2006-11-15
|
| pubmed:articleTitle |
Tissue factor pathway inhibitor gene delivery using HVJ-AVE liposomes markedly reduces restenosis in atherosclerotic arteries.
|
| pubmed:affiliation |
Department of Pathology, National Cardiovascular Center, 5-7-1 Fujishiro-dai, Suita City, Osaka, Japan.
|